American Century Ultra Fund Q4 2024 Commentary
The reelection of former President Donald Trump initially pleased investors who had worried about another protracted legal ...
3REGN : Price Over Earnings Overview: Regeneron Pharmaceuticals
In the current market session, Regeneron Pharmaceuticals Inc. REGN share price is at $695.58, after a 0.06% decrease. Over the past month, the stock spiked by 2.93%, but over the past year, it ...
Healio7h
FDA accepts sBLA, grants priority review for Dupixent to treat bullous pemphigoid
The supplemental biologics license application for Dupixent for the treatment of bullous pemphigoid in adults has been ...
JD Supra8h
First Circuit Requires But-For Causation for FCA Liability Based on AKS Violations
Key Takeaways - The First Circuit ruled in United States v. Regeneron Pharmaceuticals, Inc., that the government must prove but-for causation ...
Zacks.com on MSN10h
Pharma Stock Roundup: EU Nod to MRK's Welireg, IONS' Q4 Results & More
This week, the European Commission granted approval to Merck’s MRK novel HIF-2α inhibitor, Welireg, for two indications. The ...
Hosted on MSN10h
2 Healthcare Stocks with Big Upside and 1 to Skip
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But ...
JD Supra23h
False Claim Act Liability Under Anti-Kickback Statute Requires But-For Causation: First Circuit Narrows Liability in Growing Circuit Split
On February 18, 2025, the First Circuit Court of Appeals issued its decision in U.S. v. Regeneron Pharmaceuticals, ruling ...